Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients - Summary - MDSpire

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

  • By

  • Ahmad Alcheikh

  • Griffith B. Perkins

  • Phillippa A. Pucar

  • Amelia Cecchin

  • Cheng Sheng Chai

  • Matthew Tunbridge

  • Anouschka Akerman

  • Anupriya Aggarwal

  • Vanessa Milogiannakis

  • Stuart Turville

  • Sharon Allen

  • Pravin Hissaria

  • Tatjana Banovic

  • P. Toby Coates

  • David M. Ross

  • April 10, 2023

  • 0 min

Share

Objective:

To assess the immune response to SARS-CoV-2 vaccination in myelofibrosis patients receiving JAK inhibitors compared to healthy controls and other relevant groups.

Key Findings:
  • Myelofibrosis patients on JAK inhibitors showed severely impaired humoral and cellular immune responses compared to healthy controls (p < 0.001).
  • Seroconversion rates after two doses were significantly lower in JAKi patients (23.5%) compared to healthy controls (100%) (p < 0.0001).
  • Spike-reactive T cell responses were significantly reduced in JAKi patients compared to healthy controls (p < 0.01).
Interpretation:

The impaired immune response in myelofibrosis patients on JAK inhibitors highlights the need for tailored vaccination strategies in this vulnerable population, which could inform public health policies.

Limitations:
  • Small sample size of myelofibrosis patients, which may limit the generalizability of the findings.
  • Observational design limits causal inferences, necessitating further studies.
Conclusion:

Myelofibrosis patients receiving JAK inhibitors exhibit significantly reduced immune responses to SARS-CoV-2 vaccination, necessitating further research on vaccination strategies in this group.

Original Source(s)

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

  • by Ahmad Alcheikh, Griffith B. Perkins, Phillippa A. Pucar, Amelia Cecchin, Cheng Sheng Chai, Matthew Tunbridge, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Stuart Turville, Sharon Allen, Pravin Hissaria, Tatjana Banovic, P. Toby Coates, David M. Ross

  • April 10, 2023

Related Content

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection

Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O008)

  • November 9, 2023